Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Pegmusirudin vs Heparin in Haemodialysis
NCT00074620Phase 2Completed
- Sponsor
- Speedel
- Start
- Nov 2003
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegmusirudin in Vascular graft occlusion (2 arms), sponsored by Speedel. Primary endpoint: Safety and tolerability of SPP200. Started Nov 2003; status: completed.
02
Drugs
pegmusirudin
03
Conditions
Vascular graft occlusion
Beyond the preview
Go deeper on NCT00074620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074620.